NCT06393101View on ClinicalTrials.gov

The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome

PHASE1RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

June 1, 2029

Study Completion Date

June 1, 2029

Conditions
Complex Regional Pain Syndrome
Interventions
DRUG

BRC-002

BRC-002 is a non-scheduled cannabidiolic (CBD) formulation (\<.3% THC). The cannabinoids in BRC-002 are naturally biosynthesized within the Cannabis sativa L. plant as acidic forms of CBD (cannabidiolic acid; CBDA), THC (tetrahydrocannabinolic acid; THCA) and other minor cannabinoids.

DRUG

BRC-002 Placebo

Oral solution of mono-, di-, and triglycerides

Trial Locations (2)

92093

RECRUITING

Altman Clinical and Translational Research Institute, La Jolla

RECRUITING

University of California, San Diego, San Diego

All Listed Sponsors
lead

University of California, San Diego

OTHER